Sequential allogeneic and autologous CAR-T-cell therapy to treat an immune-compromised leukemic patient
- Resource Type
- Authors
- Yuchen Liu; Xiaochuan Chen; Shih-Ting Tsao; Lung-Ji Chang; Jian-Ping Zhang; Rui Zhang; Paul Castillo; Dao-Pei Lu
- Source
- Blood advances. 2(14)
- Subject
- 0301 basic medicine
business.industry
T-Lymphocytes
Hematology
Allografts
Immunotherapy, Adoptive
Immune compromised
03 medical and health sciences
Immunocompromised Host
030104 developmental biology
0302 clinical medicine
Text mining
030220 oncology & carcinogenesis
Child, Preschool
Lymphocyte Transfusion
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Immunology
Medicine
CAR T-cell therapy
Humans
Female
Exceptional Case Report
business
Autografts
human activities
- Language
- ISSN
- 2473-9537
Key Points CAR-T–cell therapy normally requires the patient’s own healthy T cells. An allogeneic CAR-T bridging therapy could rescue lymphopenic patients.